Literature DB >> 22190618

In vivo voltammetry monitoring of electrically evoked extracellular norepinephrine in subregions of the bed nucleus of the stria terminalis.

Natalie R Herr1, Jinwoo Park, Zoé A McElligott, Anna M Belle, Regina M Carelli, R Mark Wightman.   

Abstract

Norepinephrine (NE) is an easily oxidized neurotransmitter that is found throughout the brain. Considerable evidence suggests that it plays an important role in neurocircuitry related to fear and anxiety responses. In certain subregions of the bed nucleus of the stria terminalis (BNST), NE is found in large amounts. In this work we probed differences in electrically evoked release of NE and its regulation by the norepinephrine transporter (NET) and the α(2)-adrenergic autoreceptor (α(2)-AR) in two regions of the BNST of anesthetized rats. NE was monitored in the dorsomedial BNST (dmBNST) and ventral BNST (vBNST) by fast-scan cyclic voltammetry at carbon fiber microelectrodes. Pharmacological agents were introduced either by systemic application (intraperitoneal injection) or by local application (iontophoresis). The iontophoresis barrels were attached to a carbon fiber microelectrode to allow simultaneous detection of evoked NE release and quantitation of iontophoretic delivery. Desipramine (DMI), an inhibitor of NET, increased evoked release and slowed clearance of released NE in both regions independent of the mode of delivery. However, the effects of DMI were more robust in the vBNST than in the dmBNST. Similarly, the α(2)-AR autoreceptor inhibitor idazoxan (IDA) enhanced NE release in both regions but to a greater extent in the vBNST by both modes of delivery. Since both local application by iontophoresis and systemic application of IDA had similar effects on NE release, our results indicate that terminal autoreceptors play a predominant role in the inhibition of subsequent release.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190618      PMCID: PMC3311672          DOI: 10.1152/jn.00620.2011

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  30 in total

1.  Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat.

Authors:  Renata H Hasue; Sara J Shammah-Lagnado
Journal:  J Comp Neurol       Date:  2002-12-02       Impact factor: 3.215

2.  Overoxidation of carbon-fiber microelectrodes enhances dopamine adsorption and increases sensitivity.

Authors:  Michael L A V Heien; Paul E M Phillips; Garret D Stuber; Andrew T Seipel; R Mark Wightman
Journal:  Analyst       Date:  2003-11-11       Impact factor: 4.616

3.  The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat.

Authors:  M P Epping-Jordan; A Markou; G F Koob
Journal:  Brain Res       Date:  1998-02-16       Impact factor: 3.252

4.  Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion.

Authors:  J M Delfs; Y Zhu; J P Druhan; G Aston-Jones
Journal:  Nature       Date:  2000-01-27       Impact factor: 49.962

5.  Noradrenaline transmission within the ventral bed nucleus of the stria terminalis is critical for fear behavior induced by trimethylthiazoline, a component of fox odor.

Authors:  Markus Fendt; Stephanie Siegl; Björn Steiniger-Brach
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

6.  Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat.

Authors:  Edward G Meloni; Lyle P Gerety; Allison T Knoll; Bruce M Cohen; William A Carlezon
Journal:  J Neurosci       Date:  2006-04-05       Impact factor: 6.167

7.  Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis.

Authors:  W E Cullinan; J P Herman; S J Watson
Journal:  J Comp Neurol       Date:  1993-06-01       Impact factor: 3.215

8.  Noradrenaline triggers GABAA inhibition of bed nucleus of the stria terminalis neurons projecting to the ventral tegmental area.

Authors:  Eric C Dumont; John T Williams
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

9.  Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats.

Authors:  K Pacak; R McCarty; M Palkovits; I J Kopin; D S Goldstein
Journal:  Brain Res       Date:  1995-08-07       Impact factor: 3.252

Review 10.  Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence.

Authors:  Rachel J Smith; Gary Aston-Jones
Journal:  Brain Struct Funct       Date:  2008-07-24       Impact factor: 3.270

View more
  23 in total

1.  Effects of noradrenergic alpha-2 receptor antagonism or noradrenergic lesions in the ventral bed nucleus of the stria terminalis and medial preoptic area on maternal care in female rats.

Authors:  Carl D Smith; M Allie Holschbach; Joshua Olsewicz; Joseph S Lonstein
Journal:  Psychopharmacology (Berl)       Date:  2012-05-29       Impact factor: 4.530

2.  Bidirectional pharmacological perturbations of the noradrenergic system differentially affect tactile detection.

Authors:  Jim McBurney-Lin; Yina Sun; Lucas S Tortorelli; Quynh Anh T Nguyen; Sachiko Haga-Yamanaka; Hongdian Yang
Journal:  Neuropharmacology       Date:  2020-05-21       Impact factor: 5.250

3.  Heterogeneous extracellular dopamine regulation in the subregions of the olfactory tubercle.

Authors:  Jinwoo Park; Ken T Wakabayashi; Caitlin Szalkowski; Rohan V Bhimani
Journal:  J Neurochem       Date:  2017-06-20       Impact factor: 5.372

4.  Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy.

Authors:  Jesus-Servando Medel-Matus; Don Shin; Raman Sankar; Andrey Mazarati
Journal:  Exp Neurol       Date:  2016-12-22       Impact factor: 5.330

5.  Dorsal BNST α2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors.

Authors:  Nicholas A Harris; Austin T Isaac; Anne Günther; Kevin Merkel; James Melchior; Michelle Xu; Eghosa Eguakun; Rafael Perez; Brett P Nabit; Stephanie Flavin; Ralf Gilsbach; Brian Shonesy; Lutz Hein; Ted Abel; Arnd Baumann; Robert Matthews; Samuel W Centanni; Danny G Winder
Journal:  J Neurosci       Date:  2018-08-27       Impact factor: 6.167

6.  Noradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats.

Authors:  Carl D Smith; Christopher C Piasecki; Marcus Weera; Joshua Olszewicz; Joseph S Lonstein
Journal:  Behav Neurosci       Date:  2013-06-24       Impact factor: 1.912

7.  Ontogeny of Norepinephrine Transporter Expression and Antidepressant-Like Response to Desipramine in Wild-Type and Serotonin Transporter Mutant Mice.

Authors:  Nathan C Mitchell; Melodi A Bowman; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Pharmacol Exp Ther       Date:  2016-11-09       Impact factor: 4.030

8.  Anatomical and pharmacological characterization of catecholamine transients in the medial prefrontal cortex evoked by ventral tegmental area stimulation.

Authors:  Tatiana A Shnitko; Donita L Robinson
Journal:  Synapse       Date:  2013-11-28       Impact factor: 2.562

9.  Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder.

Authors:  Eduardo Pineda; J David Jentsch; Don Shin; Grace Griesbach; Raman Sankar; Andrey Mazarati
Journal:  Epilepsy Behav       Date:  2013-11-18       Impact factor: 2.937

10.  Stress-Induced Alterations of Norepinephrine Release in the Bed Nucleus of the Stria Terminalis of Mice.

Authors:  Karl T Schmidt; Viren H Makhijani; Kristen M Boyt; Elizabeth S Cogan; Dipanwita Pati; Melanie M Pina; Isabel M Bravo; Jason L Locke; Sara R Jones; Joyce Besheer; Zoé A McElligott
Journal:  ACS Chem Neurosci       Date:  2018-09-28       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.